Treatment of HCV infection in patients with cirrhosis

Annals of Hepatology

Volumn 9, Issue SUPPL. 1, 2010, Pages 80-83

  de Mattos, Angelo Alves ^a   de Mattos, Ângelo Zambam ^a  

^a UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

Author keywords

Cirrhosis; Hepatitis C virus; Peginterferon

Indexed keywords

PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN;

ARTICLE; COMORBIDITY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; GENOTYPE; HEPATITIS C; HUMAN; IMMUNE RESPONSE; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER TRANSPLANTATION; PORTAL HYPERTENSION; PRACTICE GUIDELINE; REMISSION; THROMBOCYTE COUNT; TREATMENT RESPONSE;

EID: 79955937690     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-1374.
2. Iacobellis A, Ippolito A, Andriulli A. Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition. World J Gastroenterol 2008; 14: 6467-6472.
3. Braks RE, Ganne-Carrie N, Fontaine H, Paries J, Grando-Lemaire V, Beaugrand M, et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007; 13: 5648-5653.
4. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G et al. Sustained virological response to interferon is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology 2007; 45: 579-587.
5. Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2010; 8: 192-199.
6. Mallet V, Gilgenkrantz H, Serpaggi J, Verkarre V, Vallet- Pichard A, Fontaine H, et al. Brief Communication: The Relationship of Regression of Cirrhosis to Outcome in Chronic Hepatitis C. Ann Intern Med 2008; 149: 399-403.
7. Melero J, Berenguer M. Antiviral therapy in patients with HCV-cirrhosis. Ann Hepatol 2009; 8: 292-297.
8. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-262.
9. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology 2006; 44: 1675-1684.
10. Tinè F, Magrin S, Craxì A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J Hepatol 1991; 13: 192-199.
11. Alves AV, Perin C, Ramos GZ, Brandão ABMB, Mattos AA, Almeida PRL. Tratamento de pacientes com hepatite crônica pelo vírus C com interferone ribavirina: a experiência da Secretaria de Saúde do RS. Arq Gastroenterol 2003; 40: 227-232.
12. Almeida PRL, Mattos AA, Amaral KM, Feltrin AA, Zanin P, Tovo CV, et al. Treatment of Hepatitis C with Peginterferon and Ribavirin in a Public Health Program. Hepato-Gastroenterol 2009; 56: 223-226.
13. Helbling B, Jochum W, Stamenic I, Knöpfli M, Cerny A, Borovicka J, et al. HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. J Viral Hepat 2006; 13: 762-769.
14. Floreani A, Baldo V, Rizzotto ER, Carderi I, Baldovin T, Minola E. Pegylated interferon alpha-2b plus ribavirin for naivepatients with HCV-related cirrhosis. J Clin Gastroenterol 2008; 42: 734-737.
15. Bruno S, Shiffman ML, Roberts SK, Gane EJ, Messinger D, Hadziyannis SJ, et al. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010; 51:388-397.
16. Di Marco V, Amasio PL, Ferraro D, Calvaruso V, Alaimo G, Peralta S. Peg-interferon alone or combined with ribavirinin HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007; 47: 484-491.
17. Giannini EG, Basso M, Savarino V, Picciotto A. Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension. J Intern Med 2009; 266: 537-546.
18. Rincon D, Ripoll C, Iacono OL, Salcedo M, Catalina MV, Alvarez E, et al. Antiviral Therapy Decreases Hepatic Venous Pressure Gradient in Patients with Chronic Hepatitis C and Advanced Fibrosis. Am J Gastroenterol 2006; 101: 2269-2274.
19. Wiesner RH, Sorrell M, Villamil F. International Liver Transplantation Society Expert Panel. Report of the first InternationalLiver Transpantation Society experts panelconsensus conference on liver transplantation and hepatitisC. Liver Transpl 2003; 9: S1-S9.
20. Iacobellis A, Siciliano M, Perri F, Annicchiarico BE, Leandro G, Caruso N, et al. Peginterferon alfa-2b and ribavirinin patients with hepatitis C virus and decompensated cirrhosis: A controlled study. J Hepatol 2007; 46: 206-212.
21. Tekin F, Gunsar Z, Karasu U, Akarca A & Ersoz G. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics. Aliment Pharmacol Ther 2008; 27: 1081-1085.
22. Iacobellis A, Siciliano M, Annicchiarico BE, Valvano MR, Niro GA, Accadia L, et al. Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients. Aliment Pharmacol Ther 2009; 30: 146-153.
23. Annicchiarico BE, Siciliano M, Avolio AW, Caracciolo G, Gasbarrini A, Agnes S, et al. Treatment of Chronic Hepatitis C Virus Infection With Pegylated Interferon and Ribavirin in Cirrhotic Patients Awaiting Liver Transplantation. Transpl Proceed 2008; 40: 1918-19120.
24. Aghemo A, Rumi MG, Monico S, Prati GM, D'Ambrosio R, Donato MF, et al. The pattern of pegylated interferon-alpha 2b and ribavirin treatment failure in cirrhotic patientsdepends on hepatitis C virus genotype. Antivir Ther 2009; 14: 577-584.
25. Carrión JA, Martínez-Bauer E, Crespo G, Ramírez S, Pérezdel- Pulgar S, García-Valdecasas JC, et al. Antiviral therapy increases the risk of bacterial infections in HCV infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol 2009; 50: 719-728.